Concepedia

Sarah Solomon

SS

Statistics

Publications

9

Citations

738

H-Index

9

Active since

2009

Affiliations

Harvard University(Current)

Brigham and Women's Hospital

Dana-Farber Cancer Institute

Oregon Health & Science University

Emory University

Sarah Solomon is an author at Harvard University specializing in pharmacology, medicine, and oncology.

Publications per year

2009–2018

9

Publications

9

Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial

Suzanne George, Qian Wang, Michael C. Heinrich et al. · Journal of Clinical Oncology · 2012 · 248 citations

, , +17

Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study

Eytan Ben‐Ami, Constance M. Barysauskas, Sarah Solomon et al. · Cancer · 2017 · 223 citations · Full text

, , +12

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy

Eytan Ben‐Ami, Constance M. Barysauskas, Margaret von Mehren et al. · Annals of Oncology · 2016 · 163 citations · Full text

, , +13

A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU).

Suzanne George, Margaret von Mehren, Michael C. Heinrich et al. · Journal of Clinical Oncology · 2011 · 28 citations

, , +12

Downregulation of CD3ζ in NK Cells from Systemic Lupus Erythematosus Patients Confers a Proinflammatory Phenotype

Abel Suárez‐Fueyo, Sean J. Bradley, Takayuki Katsuyama et al. · The Journal of Immunology · 2018 · 19 citations · Full text

, , +17

1–5 of 9